MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

Myocardial Ischemia Clinical Trial

— MICRO2  

Official title:

Magnetocardiography as a Noninvasive Diagnostic Strategy for Suspected Myocardial Ischemia With No Obstructive Coronary Artery Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06212466
• Other study ID #: MICRO 2.0
• Status: Not yet recruiting
• Start date: June 3, 2024
• Est. completion date: December 15, 2024

Study information

• Verified date: June 2024
• Source: Genetesis Inc.
• Contact: Zoe E Swann, PhD
• Phone: 4802868695
• Email: zoe.swann[@]genetesis.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.

Description:

Magnetocardiography (MCG) is a noninvasive imaging modality that has been extensively studied over the past several decades as a diagnostic imaging solution for various forms of cardiovascular disease. MCG measures the magnetic field that arises from the electrical activity of the heart's pacemaker activity, the very same activity which yields surface electric field potentials as measured by the electrocardiogram. Unlike electrocardiographic signals, however, MCG signals are undistorted by conductive tissue noise, and are highly sensitive to ischemic injury and vortex currents missed by the same electrocardiographic measurements. Accordingly, numerous clinical trials suggest the usefulness of MCG for the evaluation of ischemia in patients with suspected acute coronary syndrome.

There is a growing body of evidence demonstrating the usefulness of MCG in the detection of myocardial ischemia, both in patients with symptoms of ACS, and in patients with stable angina. Since MCG is a functional assessor of depolarization and repolarization heterogeneity, it is hypothesized that MCG may be a useful frontline diagnostic modality to identify CMD in patients who would otherwise have normal coronary CT angiograms and/or stress tests. The proposed study intends to study the diagnostic accuracy of MCG in patients with suspected INOCA.

This demonstrates a significant unmet clinical need in the assessment of patients, and especially women, with INOCA. The current standard of care for these patients is resource/time intensive and associated with a significant rate of non-diagnostic clinical data requiring expensive and invasive evaluation for safe patient management. Magnetocardiography offers the potential for rapid, safe, noninvasive, non-radiologic assessment of the INOCA population, and may lead to earlier treatment strategies for CMD patients.

From the participating clinical sites, patients age ≥18 years who presented with chest pain or exertional dyspnea concerning for myocardial ischemia with no obstructive epicardial CAD on invasive or computed tomographic coronary angiography will be screened and subsequently enrolled when meeting criteria. This is a prospective observational study used for clinical data collection for the clinical validation testing of the CardioFlux MCG system. There will be no intervention introduced by the study device. The interpretation of the CardioFlux MCG data made by the study reader(s) will not be known to the patient's treating physician. Similarly, the patient's coronary physiology data, diagnosis, or interventions made by the patient's treating physician in following the standard of care will not be known to any of the scan readers. Except for the introduction of the MCG scan, there will be no other alteration to the patient standard of care.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 135
• Est. completion date: December 15, 2024
• Est. primary completion date: December 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA

In order to be eligible to participate in this study, an individual must meet all the following criteria:

1. = 18 years of age at the time of enrollment.

2. Willing to provide written informed consent.

3. Signs and symptoms of chest pain prompted further evaluation by a coronary angiogram within the previous 5 years.

4. Invasive CFR (via bolus thermodilution) completed within 180 days, or scheduled within 30 days, of informed consent.

4.1. CFR must be performed in the mid Left Anterior Descending (LAD) vessel.

5. Successfully passing CardioFlux MCG Quality Preview prior to MCG study scan. 5.1. Patients must be able to fit into the device. 5.2. Patients must be able to lie supine for 5 minutes. 5.3. Patients must not have any of the following: 5.3.1. Presence of ferromagnetic metal between the sternal notch and costal margin of the rib cage.

5.3.2. Implanted pacemakers or cardioverter/defibrillators. 5.3.3. Implanted infusion pumps and/or neuro stimulators. 5.3.4. Note: sternotomy wires and stents are acceptable. 5.3.5. Note: Failure to meet inclusion criteria 5.3 will render the MCG scan uninterpretable. However, any patient who may be scanned with the presence of any of the above objects is not at any risk of harm by the device. Prosthetic joints are allowed if the MCG Quality Preview is acceptable.

EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Obstructive CAD (either anatomical or physiological) defined as:

1.1. = 70% lesion in any major epicardial or branch vessel by CT or invasive Angiography; 1.2. = 50% lesion in the Left Main (LM) vessel by CT or invasive Angiography; 1.3. or either an FFR<0.80 or iFR or RFR <0.89 in the obstructed vessel,

2. Any of the following cardiac pathologies:

2.1. Epicardial spasm. 2.2. History of non-ischemic dilated or hypertrophic cardiomyopathy. 2.3. Suspected myocarditis. 2.4. Documented acute coronary syndrome (ACS) within previous 30 days. 2.5. Known left ventricular ejection fraction (LVEF) <45% on most recent assessment (can be via ECHO), or hospitalization for Reduced ejection fraction within 180 days. (HFpEF is allowed).

2.6. Currently in atrial fibrillation or atrial flutter at the time of enrollment.

2.7. Complete Bundle Branch Block. 2.8. Known moderate or severe valvular disease (anything besides mild). 2.9. Known severe Left ventricular hypertrophy (LVH) as determined by Echocardiography.

2.10. Dextrocardia.

3. Known estimated glomerular filtration rate (eGFR) <30 ml/min.

4. Life expectancy <3-yrs. due to non-cardiovascular comorbidity.

5. Concurrent enrollment in a clinical trial in which therapeutic intervention is administered within 30 days of enrollment.

6. Prior enrollment in MICRO 1.0 and/or MICRO(T) data development study.

7. Pregnancy.

Related Conditions & MeSH terms

• Angina
• Coronary Artery Disease
• Coronary Microvascular Disease
• Heart Diseases
• Ischemia
• Ischemic Heart Disease
• Microvascular Angina
• Myocardial Ischemia

Intervention

Device:
• CardioFlux
The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.

Locations

Country	Name	City	State
United States	The Christ Hospital	Cincinnati	Ohio
United States	Cleveland Clinic, Cardiovascular Medicine Research	Cleveland	Ohio
United States	Ascension St. John Hospital	Detroit	Michigan
United States	University of Florida, Division of Cardiovascular Medicine	Gainesville	Florida
United States	St. Luke's Health System, Cardiovascular Research	Kansas City	Missouri
United States	Hackensack Meridian Mountainside Medical Center	Montclair	New Jersey
United States	Mayo Clinic, Cardiovascular Research	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Genetesis Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Seattle Angina Questionnaire - 7	For patients whose CFR was completed within 30 days of MCG scan, SAQ-7 scores may be measured and analyzed.	30 days
Other	Comparison of functional vs structural CMD	Comparison of functional vs structural CMD will be analyzed (endothelial dependent vs independent).	6 months
Primary	Diagnostic accuracy of CardioFlux MCG in determining the presence of CMD	Diagnostic accuracy of CardioFlux MCG in determining the presence of coronary microvascular dysfunction, as measured by AUC with ground truth defined as an invasive CFR <2.5 for bolus thermodilution method.; H0: AUC<0.55 Ha: AUC=0.55	6 months
Secondary	Sensitivity and specificity in determining presence of CMD (Rule In)	Patients who have confirmed presence of CMD via invasive CFR: Sensitivity and specificity of CardioFlux MCG in determining the presence of CMD with the gold standard defined as an invasive CFR <2.5 for thermodilution method as determined by a positive MCG scan output as defined by a Magnetic Dispersion Dynamics (MDD) score less than 41 fT/ms.; Sensitivity; H0<0.30; Ha=0.30; Specificity; H0<0.70; Ha =0.70	6 months
Secondary	Sensitivity and specificity in determining presence of CMD (Rule Out)	Patients who have confirmed absence of CMD via invasive CFR: Sensitivity; H0<0.70; Ha=0.70; Specificity; H0<0.30; Ha =0.30	6 months
Secondary	ROC/AUC, sensitivity and specificity at CFR cut-offs of <2.0 and 3.0.	ROC/AUC, sensitivity and specificity for invasive CFR by thermodilution methods at CFR cut-offs of <2.0 and 3.0.	6 months
Secondary	Patient-Reported Experiences with CardioFlux	Self-reported questionnaire (5 questions scored 1 (very dissatisfied) to 5 (very satisfied) with a minimum score of 5 and a maximum score of 25.	6 months
Secondary	Participant Age	Age (years)	6 months
Secondary	Participant Height	in meters; if known	6 months
Secondary	Participant Weight	in kilograms; if known	6 months
Secondary	Participant Gender at Birth	Male/Female	6 months
Secondary	Index of Microvascular Resistance (IMR)	Sensitivity, Specificity, and ROC/AUC for CardioFlux will also be calculated against Index of Microvascular Resistance (IMR), defined as >25.	6 months
Secondary	Comparison of bolus vs. continuous thermodilution	Comparison of bolus thermodilution (CFR-bolus) and continuous thermodilution (CFR-cont) against MCG when CFR-cont is available.	6 months
Secondary	Number of Adverse Events	Safety will be monitored by the reporting of adverse events (related and non-related to the device) throughout the trial.	6 months